Imricor Medical Systems, Inc. · ASX:IMR
Imricor Medical Systems — Canaccord Drug & Device Conference Noosa 2025
12 slides from Imricor Medical Systems's conference presentation, Oct 21, 2025
Slide 1: Canaccord Drug & Device Conference Noosa 2025
For personal use only Canaccord Drug & Device Conference Noosa 2025 Imricor's vision is to bring iCMR to every cardiac centre in the world IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 2: Disclaimer
Disclaimer The material contained in this document is a presentation of general background developments and their potential effect upon Imricor. There can be no assurance that future For personal use only information on Imricor Medical Systems, Inc. (Imricor) and its activities current as of the dat
Slide 3: Imricor is moving cardiac ablations from X-Ray Cath Labs to MRI Cath Labs
Imricor is moving cardiac ablations For personal use only from X-Ray Cath Labs to MRI Cath Labs 100% of consumable revenue captured Investor Presentation, September Canaccord 2021 Drug & Device Conference 2025 | 3
Slide 4: Cardiac Ablation
Cardiac Ablation For personal use only Minimally invasive procedure to treat arrhythmias (irregular heartbeats) 1 in 4 people over the age of 74 will develop an arrhythmia Over 1.2m cardiac ablations are performed annually Success rates range from 40%-95% depending on the type of arrhythmia Investor
Slide 5: A strong and growing market in cardiac ablation
A strong and growing market in cardiac ablation A large global addressable market with high growth potential supported by favourable growth drivers For personal use only DRIVERS OF GLOBAL CATHETER Electrophysiology Devices Market Size US12$bn ABLATION MARKET 40 35 15% CAGR Increased incidence of car
Slide 6: MRI Cath Lab (iCMR Lab) economics
MRI Cath Lab (“iCMR Lab”) US Top 50 Hospitals by volume AFL VT Afib Total For personal use only Economics: Average procedures pa 434 173 1010 1617 Imricor ASP US$ per procedure $4000 $6500 $6500 Imricor Revenue opportunity per hospital US$ $1.7m $1.1m $6.6m $9.43m Device cost savings per hospital pa
Slide 7: Imricor Regulatory Status – Unlocking the world's markets
Imricor Regulatory Status – Unlocking the world’s markets Geography Regulation Imricor Product Suite Pathway Status Details For personal use only • NorthStar • Advantage-MR EP Recorder/Stimulator • Vision-MR Diagnostic Catheter 2.0 Med Full technology platform to perform real-time • Vision-MR Diagno
Slide 8: Pipeline benefiting from investment in sales
Pipeline benefiting from investment in sales For personal use only European active pipeline is rebuilding Imricor’s products are currently 30 approved in 31 countries, with 8 DRIVERS OF GLOBAL CATHETER countries containing customer sites ABLATION MARKET 25 Estimated over 1,000,000 ablation Increased
Slide 9: Becoming a global med-tech company
Becoming a global med-tech company For personal use only Current iCMR lab countries Pipeline iCMR lab countries Germany France Sweden Italy Lithuania Denmark Netherlands Switzerland Greece Norway Poland Latvia Croatia Hungary Saudi Arabia Netherlands United States* Qatar Germany *Clinical site Switz
Slide 10: The Journey of Developing a New Medical Device
The Journey of Developing a New Medical Device For personal use only Regulatory Invention Development Commercialisation Approval Education & Training Continuous Across All Stages and All Stakeholders Physicians Hospitals Investors Regulators Policy Makers OEM Partners Payers Investor Presentation, S
Slide 11: Imricor Leadership: Management
Imricor Leadership: Management For personal use only STEVE WEDAN JONATHON GUT GREGG STENZEL NICK CORKILL NICK TWOHY President and Chief Executive Officer, Vice President of Finance and Chief Chief Operating Officer Vice President Vice President of Marketing and Board Chair Financial Officer Corporat
Slide 12: Contact Information
Contact Information For personal use only Investors & Australian Media: Simon Hinsley NWR Communications simon@nwrcommunications.com.au +61 401 809 653 Investors: Steve Wedan Executive Chair, President & CEO Email: steve.wedan@imricor.com Nick Corkill Vice President, Corporate Strategy Email: nick.c
Imricor Medical Systems — Canaccord Drug & Device Conference Noosa 2025 on 6ix